Literature DB >> 29076589

Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.

Archana Rastogi1, Saggere Muralikrishna Shasthry2, Ayushi Agarwal3, Chhagan Bihari1, Priyanka Jain4, Ankur Jindal2, Shiv Sarin2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an increasingly common cause of chronic liver disease. Till date, liver biopsy remains the gold standard for identification and quantification of the wide histological spectra of NAFLD. Histological scorings are very useful and widely applied for the diagnosis and management in clinical trials and follow-up studies of non-alcoholic steatohepatitis (NASH). However, in view of scarce published literature, there is a need to evaluate them in large cohort of NAFLD. This study was aimed to evaluate the two histological scoring systems (NAS-CRN, SAF) in the diagnosis of NAFLD and to assess the role of histological characteristics as injury markers in NAFLD. Retrospective histological study of liver biopsies of 1000 patients diagnosed as NAFLD, between 2010 and 2016, was conducted. Histopathologic evaluation and semiquantiative scoring based on NAS-CRN and SAF algorithm and their correlation with serum aminotransferase and fibrosis were performed. Liver biopsies were classified according to the NAS-CRN scoring, as NAS <3 (not NASH) in 72 (7.2%), NAS 3-4 (borderline NASH) in 310 (31%), and NAS ≥5 (definite NASH) in 618 (61.8%), and SAF classified 117 (11.7%) not NASH and 883 (88.3%) definite NASH. There was excellent concordance for definite NASH and not NASH; however, 88.06% of borderline NASH was classified as NASH by SAF. 76.39% by NAS and 78.63% by SAF algorithm who were diagnosed as not NASH showed the presence of fibrosis; however, higher stages of fibrosis were significantly more prevalent in definite NASH, excluding burnt-out cirrhosis. Serum ALT was significantly associated with increasing stages of fibrosis (p < 0.001) and the three categories (not NASH, borderline NASH, and definite NASH) when classified as with/without fibrosis (p < 0.001). Steatosis of higher grades, more ballooned cells, and more foci of Lobular Inflammation were found in significantly higher proportion of patients with NASH (p < 0.001), with higher fibrosis stages (p < 0.001) and higher serum ALT levels (p < 0.001). NAFLD classifications based on histological scoring NAS-CRN and SAF algorithm are concordant for the category of definite NASH and not NASH, while borderline NASH shows discrepant interpretation. There was highly significant correlation between the NAS and SAF categories with high grades of histological characteristics, with serum ALT and with higher stages of fibrosis. Exclusion of fibrosis is a limitation with both scores.
© 2017 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; histology; non-alcoholic steatohepatitis; scoring

Mesh:

Substances:

Year:  2017        PMID: 29076589     DOI: 10.1111/apm.12742

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  11 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

2.  Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2.

Authors:  Bin Liu; Liping Xiang; Jing Ji; Wei Liu; Ying Chen; Mingfeng Xia; Yuejun Liu; Wenyue Liu; Peiwu Zhu; Yi Jin; Yu Han; Jieli Lu; Xiaoying Li; Minghua Zheng; Yan Lu
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

Review 3.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

4.  FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.

Authors:  Arka De; Amarjit Keisham; Saurabh Mishra; Manu Mehta; Nipun Verma; Madhumita Premkumar; Sunil Taneja; Ashim Das; Virendra Singh; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2021-06-15

5.  Incidence of nonalcoholic fatty liver disease in patients undergoing laparoscopic cholecystectomy.

Authors:  Ranendra Hajong; Malaya Ranjan Dhal; Narang Naku; Buru Kapa
Journal:  J Family Med Prim Care       Date:  2018 Nov-Dec

6.  Risk factors and prediction model for nonalcoholic fatty liver disease in northwest China.

Authors:  Danting Li; Meiyu Zhang; Shengli Wu; Huiwen Tan; Nong Li
Journal:  Sci Rep       Date:  2022-08-16       Impact factor: 4.996

Review 7.  The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider.

Authors:  Nicolás Salva-Pastor; Norberto C Chávez-Tapia; Misael Uribe; Natalia Nuño-Lámbarri
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

8.  A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease.

Authors:  Sara Diels; Bart Cuypers; Asta Tvarijonaviciute; Bruno Derudas; Evelien Van Dijck; An Verrijken; Luc F Van Gaal; Kris Laukens; Philippe Lefebvre; Jose J Ceron; Sven Francque; Wim Vanden Berghe; Wim Van Hul
Journal:  Clin Epigenetics       Date:  2021-08-13       Impact factor: 6.551

9.  Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD.

Authors:  Lorena Pantano; George Agyapong; Yang Shen; Zhu Zhuo; Francesc Fernandez-Albert; Werner Rust; Dagmar Knebel; Jon Hill; Carine M Boustany-Kari; Julia F Doerner; Jörg F Rippmann; Raymond T Chung; Shannan J Ho Sui; Eric Simon; Kathleen E Corey
Journal:  Sci Rep       Date:  2021-09-10       Impact factor: 4.379

Review 10.  Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis.

Authors:  Vicneswarry Dorairaj; Siti Aishah Sulaiman; Nadiah Abu; Nor Azian Abdul Murad
Journal:  Biomedicines       Date:  2021-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.